MAIA Biotechnology Aktie

1,90 USD -0,08 USD -4,19 %

nachbörslich07.02.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.48,56 Mio. EUR

Div. Rendite0,00%

WKNA3DGQQ

ISINUS5526411021

SymbolMAIA

MAIA Biotechnology Aktien News

Sortieren:Datum Meistgelesen

10.01.25BusinesswireMAIA Biotechnology to Present at Biotech Showcase 2025

07.01.25BusinesswireMAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

19.12.24BusinesswireMAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

16.12.24BusinesswireMAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

10.12.24BusinesswireMAIA Biotechnology Announces Private Placement of Approximately $950,000

03.12.24BusinesswireMAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

07.11.24BusinesswireMAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

05.11.24BusinesswireMAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

29.10.24BusinesswireMAIA Biotechnology Announces $2.44 Million Private Placement

15.10.24BusinesswireMAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

10.09.24BusinesswireMAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

04.09.24BusinesswireMAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

23.07.24BusinesswireMAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

07.06.24BusinesswireMAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy

06.06.24BusinesswireMAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

04.06.24BusinesswireMAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer

17.05.24BusinesswireMAIA Biotechnology to Present at the BIO International Convention 2024

16.05.24BusinesswireMAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

30.04.24BusinesswireMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

29.04.24BusinesswireMAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

23.04.24BusinesswireMAIA Biotechnology Announces $1.00 Million Private Placement

05.04.24BusinesswireMAIA Biotechnology to Present at Two Investor Conferences in April 2024

28.03.24BusinesswireMAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

26.03.24BusinesswireMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

26.03.24BusinesswireMAIA Biotechnology Announces $1.33 Million Private Placement

22.03.24BusinesswireMAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

21.03.24BusinesswireMAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

07.03.24BusinesswireMAIA Biotechnology to Participate in the 36th Annual ROTH Conference

06.03.24BusinesswireMAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

06.03.24BusinesswireMAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

05.03.24BusinesswireMAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders

07.02.24BusinesswireMAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

24.01.24BusinesswireMAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

17.01.24BusinesswireMAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

05.01.24BusinesswireMAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

19.12.23BusinesswireMAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

17.11.23BusinesswireMAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

15.11.23BusinesswireMAIA Biotechnology Announces $4 Million Registered Direct Offering

10.11.23BusinesswireFDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

07.11.23BusinesswireMAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

MAIA Biotechnology News

MAIA Biotechnology News: auf dieser Seite finden Sie alle MAIA Biotechnology News und Nachrichten zur MAIA Biotechnology Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MAIA Biotechnology News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MAIA Biotechnology News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.